PMID: 9531331Apr 8, 1998Paper

Acute leukaemia in Jehovah's Witnesses

British Journal of Haematology
J O CullisA G Smith

Abstract

The refusal of Jehovah's Witnesses with leukaemia to accept transfusion provides a major clinical challenge because of the myelosuppressive effects of chemotherapy. Experience in treating five such patients is described. Two patients with acute lymphoblastic leukaemia (ALL) achieved remission following chemotherapy, the first without transfusion support, the second, a minor, receiving transfusion under a court order: the first patient remains in remission 5 years later, whereas the second subsequently relapsed and died. Of three patients with acute myeloid leukaemia (AML), two received chemotherapy: one died of anaemia during induction chemotherapy whereas the second eventually consented to transfusion but died of refractory leukaemia. The third patient died of anaemia despite erythropoietin. We feel Jehovah's Witnesses should not be denied antileukaemic therapy if they fully understand the risks involved. Minimizing phlebotomy, use of antifibrinolytic agents and growth factors may make chemotherapy feasible, especially in ALL where remission may be induced with less myelosuppressive agents. The outlook for those with AML treated with conventional chemotherapy appears poor; alternative approaches to treatment should be consider...Continue Reading

References

Jun 1, 1992·American Journal of Hematology·P M DainerG P Sartiano
Mar 15, 1990·The New England Journal of Medicine·S L GoldbergG P Schechter
Mar 15, 1985·Hospital Practice·D R Boggs
Sep 1, 1989·Archives of Internal Medicine·J R BartholomewW R Bell
Mar 1, 1988·British Journal of Haematology·C F HoyleF G Hayhoe
Apr 1, 1985·British Journal of Haematology·R T PerriM M Oken
Nov 1, 1985·Scandinavian Journal of Haematology·H S Garewal, B G Durie
Oct 28, 1995·BMJ : British Medical Journal·D Busuttil, A Copplestone
Jun 1, 1993·American Journal of Hematology·T NousiainenR Lahtinen

❮ Previous
Next ❯

Citations

Oct 3, 2002·British Journal of Haematology·Judith C W Marsh, David H Bevan
Jun 15, 2007·International Journal of Hematology·Shinya FujisawaMasahide Kobayashi
Apr 10, 2008·Leukemia & Lymphoma·Nicole M BrownPatricia A Ford
May 20, 2003·British Journal of Haematology·C J BartonD Mabin
Apr 20, 2004·European Journal of Haematology·Daniele LaszloGiovanni Martinelli
Mar 14, 2014·Journal of Chemotherapy·Louise ZhouTroy Guthrie
Aug 20, 2002·The Oncologist·Kristine A KnutiRichard T Penson
Nov 7, 2019·British Journal of Haematology·Firas El Chaer, Karen K Ballen
Mar 29, 2000·Pediatric Hematology and Oncology·U KohderaY Kobayashi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.